Oxford University Press

SHERPA: Yellow

People

  1. Drilon
    Drilon
  2. Motzer
    Motzer
  3. Mellinghoff
    Mellinghoff
  4. Shuman
    Shuman
  5. Rosenblum
    Rosenblum
  6. Dunkel
    Dunkel
  7. Karajannis
    Karajannis
  8. Saltz
    Saltz
  9. Souweidane
    Souweidane
  10. Panageas
    Panageas

Groups

  1. Department of Medicine (1995)
  2. Solid Tumor Oncology Division (1624)
  3. GSK Faculty (765)
  4. Survivorship Research (639)
  5. Population Sciences Research Program (615)
  6. Epidemiology and Biostatistics (465)
  7. Department of Pathology and Laboratory Medicine (415)
  8. Gastrointestinal Oncology Service (386)
  9. Genitourinary Oncology Service (367)
  10. Tow Center for Developmental Oncology (TCDO) (352)
Search Within
Formats
  1. Journal Article (2107)
  2. Meeting Abstract (2072)
  3. Book Section (192)
  4. Review (92)
  5. Editorial (84)
  6. Guidelines (36)
  7. Correspondence (26)
  8. Book Whole (18)
  9. Conference Paper (15)
  10. Research Letter (10)
Groups
  1. Department of Medicine (1995)
  2. Solid Tumor Oncology Division (1624)
  3. GSK Faculty (765)
  4. Survivorship Research (639)
  5. Population Sciences Research Program (615)
  6. Epidemiology and Biostatistics (465)

More Groups

People
  1. Lisa De Angelis (119)
  2. Alexander Drilon (108)
  3. Robert Motzer (96)
  4. Ingo Mellinghoff (93)
  5. Stewart Shuman (88)
  6. Marc Rosenblum (87)

More People

Years
  1. 2025 (105)
  2. 2024 (304)
  3. 2023 (320)
  4. 2022 (331)
  5. 2021 (323)
  6. 2020 (325)

More Years

Publications
  1. Annals of Oncology (1670)
  2. Neuro-Oncology (846)
  3. JNCI: Journal of the National Cancer Institute (485)
  4. Nucleic Acids Research (210)
  5. Clinical Infectious Diseases (138)
  6. American Journal of Clinical Pathology (106)

More Publications

Results (4652)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Dose expansion results of the bifunctional EGFR/TGFb inhibitor BCA101 with pembrolizumab in patients with recurrent, metastatic head and neck squamous cell carcinoma
    Meeting Abstract

    Hanna, G. J.; Kaczmar, J.; Zandberg, D. P.; Wong, D. J.; Yilmaz, E.; Sherman, E. J.; Calvo, A. H.; Sacco, A. G.; Bohr, D.; Reiners, R.; more...
    Annals of Oncology (2023)

    Fulltext@MSK | Save
  • Clinical and translational data from the phase I SURPASS trial of ADP-A2M4CD8 T cell receptor (TCR) T cell therapy alone or combined with nivolumab in solid tumors
    Meeting Abstract

    Garcia, V. M.; Calvo, E.; Asch, A.; Butler, M.; Zugazagoitia, J.; Charlson, J.; Cervantes, A.; Van Tine, B.; Aggen, D.; Clarke, J.; more...
    Annals of Oncology (2023)

    Fulltext@MSK | Save
  • Phase I study of ceralasertib (cerala) in combination with AZD5305 in patients (pts) with advanced/metastatic ovarian cancer (OC) previously treated with PARP inhibitors (PARPis)
    Meeting Abstract

    Shapiro, G. I.; Basu, B.; El-Khoueiry, A. B.; Postel-Vinay, S.; Im, S. A.; Rha, S. Y.; Friedman, C. F.; Italiano, A.; Kim, Y. M.; Lim, M. C.; more...
    Annals of Oncology (2023)

    Fulltext@MSK | Save
  • Isolation of cell-free DNA of patients with mucosa-associated lymphoid tissue (MALT) lymphoma
    Meeting Abstract

    Berger, J. M.; Kienzle, A.; Hatziioannou, T.; Tomasich, E.; Mayerhoefer, M.; Kiesewetter-Wiederkehr, B.; Berghoff, A. S.; Preusser, M.; Raderer, M.
    Annals of Oncology (2023)

    Fulltext@MSK | Save
  • Sacituzumab govitecan (SG) in patients (pts) with relapsed/refractory (R/R) advanced head and neck squamous cell carcinoma (HNSCC): Results from the phase II TROPiCS-03 basket trial
    Meeting Abstract

    Michel, L.; Jimeno, A.; Sukari, A.; Beck, T.; Chiu, J. W. Y.; Ahern, E. S.; Hilton, J.; Hollebecque, A.; Zanetta, S.; Patel, J.; more...
    Annals of Oncology (2023)

    Fulltext@MSK | Save
  • Combined patient specific tumor and HPV sequencing enables high sensitivity detection of ctDNA in HPV-associated oropharyngeal carcinoma patients
    Meeting Abstract

    Diplas, B. H.; Brown, D.; Pei, X.; Graybill, C.; Novaj, A.; Korn, W. M.; Daber, R.; Humm, J.; Shukla-Dave, A.; Schoder, H.; more...
    Annals of Oncology (2023)

    Fulltext@MSK | Save
  • First-in-human study of ELU001, a targeted nanoparticle drug conjugate, in subjects with folate receptor α (FRα) overexpressing solid tumors
    Meeting Abstract

    Ma, W. W.; Orr, D.; Perez, C. A.; Murciano-Goroff, Y. R.; Hamilton, E. P.; Zhao, Y.; Anders, C.; Adams, G. P.; Reddick, C.; McClintock, H. W.; more...
    Annals of Oncology (2023)

    Fulltext@MSK | Save
  • Interim results from a phase I/II study of HPN328, a tri-specific, half-life (T1/2) extended DLL3-targeting T cell engager in patients (pts) with small cell lung cancer (SCLC) and other neuroendocrine neoplasms (NEN)
    Meeting Abstract

    Choudhury, N.; Jain, P.; Dowlati, A.; Thompson, J.; Johnson, M. L.; Mamdani, H.; Sanborn, R. E.; Schenk, E. L.; Aggarwal, R.; Sankar, K.; more...
    Annals of Oncology (2023)

    Fulltext@MSK | Save
  • Outcomes for patients (pts) with advanced endometrial cancer (aEC) who completed pembrolizumab (pembro) and continued lenvatinib (LEN) in the phase III Study 309/ KEYNOTE-775
    Meeting Abstract

    Colomba, E.; Lorusso, D.; Mackay, H.; Moore, R.; Yonemori, K.; Kim, Y. M.; Sanli, U. A.; Xie, R.; Barresi, G.; McKenzie, J.; more...
    Annals of Oncology (2023)

    Fulltext@MSK | Save
  • Ubamatamab (MUC16xCD3 bispecific antibody) with cemiplimab (anti-PD-1 antibody) in recurrent ovarian cancer: Phase I dose-escalation study
    Meeting Abstract

    O'Cearbhaill, R. E.; Moore, K. N.; Yeku, O.; Liu, J. F.; Bouberhan, S.; Hamilton, E. P.; Hou, J. Y.; Van Nieuwenhuysen, E.; Papadimitriou, K.; Yoo, S. Y.; more...
    Annals of Oncology (2023)

    Fulltext@MSK | Save